Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases

• Published in: Oncotarget Vol. 7; no. 50; pp. 82074 - 82084
• Main Authors: Wu, Min, Yu, Qingxiong, Li, Qingfeng
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 13.12.2016
• Subjects: 5-alpha Reductase Inhibitors - adverse effects; Adverse Drug Reaction Reporting Systems; Alopecia - diagnosis; Alopecia - drug therapy; Alopecia - physiopathology; Drug-Related Side Effects and Adverse Reactions - etiology; Drug-Related Side Effects and Adverse Reactions - metabolism; Drug-Related Side Effects and Adverse Reactions - pathology; Drug-Related Side Effects and Adverse Reactions - physiopathology; Female; Fetus - drug effects; Fetus - metabolism; Fetus - pathology; Finasteride - adverse effects; Gene Expression Regulation - drug effects; Gene Regulatory Networks - drug effects; Hair - drug effects; Hair - growth & development; Humans; Male; Minoxidil - adverse effects; Reproduction - drug effects; Research Paper: Pathology; Risk Assessment; Risk Factors; Sex Factors; United States; United States Food and Drug Administration; Uterus - drug effects; Uterus - metabolism; Uterus - physiopathology; FDA adverse event reporting system; Pathology Section; minoxidil; alopecia; finasteride; reproductive toxicity

Alopecia is a dermatological condition with limited therapeutic options. Only two drugs, finasteride and minoxidil, are approved by FDA for alopecia treatment. However, little is known about the differences in adverse effects between these two drugs. We examined the clinical reports submitted to the...